natgillin/translations-raw huggingface dataset:
I 'induktionsfasen' gives Vistide som infusion af en times varighed 5 mg pr/kg legemsvægt én gang ugentligt i de første to uger.
During the ‘induction’ phase, Vistide is given as a one-hour infusion of 5 mg per kilogram body weight once a week for the first two weeks.
i 0,5 ml.
in 0.5 ml.
I 1 til 24 mg/kg kohorterne steg de højeste serumkoncentrationer (Cmax) efter den første dosis omtrent proportionalt med dosis, og fordelingsvolumenet var i overensstemmelse med den indledende fordeling i plasmakompartmentet.
In the 1- to 24 mg/kg cohorts, peak serum concentrations (Cmax) after the first dose increased in approximate proportion to dose and volume of distribution was consistent with initial distribution into the plasma compartment.
I 1. linjebehandlingen var den mediane progressionsfri overlevelse i intent-to-treat-populationen 5,8 måneder (95 % konfidensinterval 5,1 - 6,2 måneder) for capecitabin-monoterapi og 7,8 måneder (95 % konfidensinterval 7,0 - 8,3 måneder, p = 0,0002) for XELIRI.
In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI.
I 1. linjebehandlingen var den mediane progressionsfri overlevelse i intent-to-treat-populationen 5,8 måneder (95 % konfidensinterval 5,1 – 6,2 måneder) for capecitabin-monoterapi og 7,8 måneder (95 % konfidensinterval 7,0 -8,3 måneder; p = 0,0002) for XELIRI.
In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI.
I 1. linjebehandlingen var den mediane progressionsfri overlevelse i intent-to-treat-populationen 5,8 måneder (95 % konfidensinterval 5,1-6,2 måneder) for capecitabin-monoterapi og
In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI.
I 10 kliniske studier var medianen for gennemsnitlige og maksimale plasmakoncentrationer hos individuelle forsøgspersoner på tværs af studierne henholdsvis 2425 ng/ml (inter-kvartil fra 1193 til 4380 ng/ml) og 3742 ng/ml (inter-kvartil fra 2027 til 6302 ng/ml).
In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (inter- quartile range 2027 to 6302 ng/ml), respectively.
I 10 kliniske studier var medianen for gennemsnitlige og maksimale plasmakoncentrationer hos individuelleforsøgspersoner personer på tværs af studierne henholdsvis 2425 ng/ml (inter-kvartil fra 1193 til 4380 ng/ml) og 3742 ng/ml (inter-kvartil fra 2027 til 6302 ng/ml).
In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (inter- quartile range 2027 to 6302 ng/ml), respectively.
I 100 % humant serum var den gennemsnitlige ændring i proteinfoldning en faktor 75, hvilket resulterede i en proteinjusteret IC90-værdi på 0,064 ug/ml.
In 100% human serum, the mean fold shift for dolutegravir activity was 75 fold, resulting in protein adjusted IC90 of 0.064 ug/mL.
I 100 % humant serum var den gennemsnitlige ændring i proteinfoldning en faktor 75, hvilket resulterede i en proteinjusteret IC90-værdi på 0,064 ug/ml.
In 100% human serum, the mean protein fold shift was 75 fold, resulting in protein adjusted IC90 of 0.064 ug/mL.
I 102. uge var 49 patienter stadig på infliximab- behandling, og blandt disse var 30 (61 %) BASDAI 50 responders.
102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were BASDAI 50 responders.
I 102. uge var 49 patienter stadig på infliximab- behandling, og blandt disse var 30 (61 %) BASDAI 50 responders.
At 102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were BASDAI 50 responders.
I 102. uge var 80 patienter stadig på infliximab-behandling og blandt disse var 71 (89 %) ASAS 20 responders.
102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
I 11 kliniske undersøgelser med forskellige indikationer blev 247 patienter behandlet med Zavesca i doser på 50-200 mg t.i.d. i en periode på gennemsnitligt 2,1 år.
In 11 clinical trials in different indications 247 patients were treated with Zavesca at dosages of 50- 200 mg t.i.d. for an average duration of 2.1 years.
I 114 tilfælde var der ingen tilknyttede systemiske hændelser, og disse tilfælde synes at udgøre en lokaliseret ekstremt blegende effekt.
In 114 cases there were no associated systemic events and these cases appear to represent a localised over-whitening effect.
i 12 uger
for 12 weeks
I 14 dages (50, 150, 450 mg/kg) orale toksicitetsstudier af rotter var der tegn på adaptive lever- og thyroidforandringer.
In 14-day (50, 150 or 450 mg/kg) oral toxicity studies in rats there was evidence of adaptive hepatic and thyroid changes.
I 16 uger derefter modtog samtlige patienter Ilaris hver ottende uge.
In the following 16 weeks, all patients received Ilaris every eight weeks.
I 2 fase 1-studier blev det konkluderet, at potentialet for jernoverbelastning er minimal, og der er ikke observeret dosisafhængige virkninger hos raske frivillige.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose-dependent effects were observed in healthy volunteers.
I 2 kontrollerede kliniske studier blev 955 trombocytopeniske patienter med HCV infektion behandlet med eltrombopag.
In 2 controlled clinical studies 955 thrombocytopenic patients with HCV infection were treated with eltrombopag.
I 2 kontrollerede kliniske studier vedr. kombinationsterapi med andre antiretrovirale lægemidler, hvor 1.806 voksne patienter fik atazanavir 400 mg 1 gang dagligt (1.151 patienter, 52 ugers median varighed og 152 ugers maksimal varighed) eller atazanavir 300 mg boostet med ritonavir 100 mg gang dagligt (655 patienter, 96 ugers median varighed og 108 ugers maksimal varighed), var de hyppigst rapporterede bivirkninger kvalme, diarre og gulsot.
In 2 controlled clinical studies for combination therapy with other antiretroviral medicinal products 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg boosted with ritonavir 100 mg once daily (655 patients, 96 weeks median duration and 108 weeks maximum duration), the most frequently reported adverse reactions were nausea, diarrhoea and jaundice.
I 2 kontrollerede kliniske studier, blev 171 pædiatriske kroniske ITP-patienter behandlet med eltrombopag.
In 2 controlled clinical studies, 171 chronic paediatric ITP patients were treated with eltrombopag.
I 2 korterevarende (24-timers) placebokontrollerede forsøg med 554 skizofrene, voksne patienter med agitation og adfærdsforstyrrelser, var ABILIFY injektionsvæske, opløsning forbundet med statistisk signifikant større forbedringer i agitation/adfærdssymptomer sammenlignet med placebo og svarende til haloperidol.
In two short- term (24-hour) placebo-controlled trials involving 554 schizophrenic adult patients presenting with agitation and disturbed behaviours, ABILIFYsolution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to haloperidol.
I 2 pivotale, dobbeltblindede, placebokontrollerede, kliniske studier blev i alt 424 patienter med euvolæmisk eller hypervolæmisk hyponatriæmi (serum-natrium <135 mEq/l) grundet en række underliggende årsager (hjertesvigt, levercirrhose, SIADH m.fl.) behandlet i 30 dage med tolvaptan (n=216) eller placebo (n=208) med en indledende dosis på 15 mg dagligt.
In 2 pivotal, double-blind, placebo-controlled, clinical trials, a total of 424 patients with euvolaemic or hypervolaemic hyponatraemia (serum sodium <135 mEq/l) due to a variety of underlying causes (heart failure [HF], liver cirrhosis, SIADH and others) were treated for 30 days with tolvaptan (n=216) or placebo (n=208) at an initial dose of 15 mg/day.
I 2 randomiserede, dobbeltblinde vehikelkontrollerede studier havde patienterne i Nevanac-gruppen væsentligt mindre inflammation (celler og flare i kammervæske) i den tidlige postoperative periode til endt behandling end patienterne i vehikel-gruppen.
In two double-masked, randomised vehicle-controlled studies, patients treated with NEVANAC had significantly less inflammation (aqueous cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.
I 2 randomiserede, dobbeltblinde, parallelgruppe-studier indgik tidligere antikoagulansbehandlede patienter.
Two randomized, parallel group, double-blind studies were performed in patients previously treated with anticagulation therapy.
I 2 studier med forlænget intervaldosering af epoetin alfa (3 gange ugentligt, én gang ugentligt, én gang hver anden uge og én gang hver 4. uge) opretholdt nogle patienter ikke tilstrækkelige hæmoglobinniveauer ved længere doseringsintervaller og nåede protokoldefinerede tilbagetrækningskriterier for hæmoglobin (0 % i gruppen med dosering én gang ugentligt, 3,7 % i gruppen med dosering én gang hver anden uge og 3,3 % i gruppe med dosering én gang hver 4. uge).
In 2 studies with extended interval dosing of epoetin alfa (3 times per week, once weekly, once every 2 weeks, and once every 4 weeks) some patients with longer dosing intervals did not maintain adequate haemoglobin levels and reached protocol-defined haemoglobin withdrawal criteria (0% in once weekly, 3.7% in once-every-2-weeks, and 3.3% in the once-every-4-weeks groups).
I 2 studier med længere interval mellem erythropoietindoser (3 gange om ugen, en gang ugentligt, en gang hver 2. uge og en gang hver 4. uge) havde nogle patienter ikke et tilstrækkeligt hæmoglobinniveau ved længere dosisintervaller, men opfyldte det protokoldefinerede kriterie for seponering for lavt hæmoglobin (0% ved en gang ugentligt, 3,7% ved en gang hver 2. uge og 3,3% ved en gang hver 4. uge).
In 2 studies with extended interval dosing of erythropoietin (3 times per week, once weekly, once every 2 weeks and once every 4 weeks) some patients with longer dosing intervals did not maintain adequate haemoglobin levels and reached protocol-defined haemoglobin withdrawal criteria (0% in once weekly, 3.7% in once-every-2-weeks and 3.3% in the once-every-4-weeks groups).
i 2-5 dage
for 2-5 days
I 2-årige orale carcinogenicitetsstudier var den højeste dronedarondosis der blev administreret i 24 måneder 70 mg/kg/dag i rotter, og 300 mg/kg/dag i mus.
In 2-year oral carcinogenicity studies, the highest dronedarone dose administered for 24 months was 70 mg/kg/day in rats and 300 mg/kg/day in mice.
I 2-årige subkutane karcinogenicitetsstudier blev ikke-dødelige C-celle-thyroideakarcinomer set hos rotter og mus, og anses at være forårsaget af en ikke-genotoksisk GLP-1 receptor-medieret mekanisme, som gnavere er specielt følsomme overfor.
In 2-year subcutaneous carcinogenicity studies, non-lethal C-cell thyroid tumors were seen in rats and mice and are considered to be caused by a non-genotoxic GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive.
I 2-årige subkutane karcinogenicitetsstudier hos mus sås 3 tilfælde af adenokarcinomer i endometriet i middeldosis-gruppen med en signifikant stigning svarende til eksponeringsratio på 97- fold.
In 2-year subcutaneous carcinogenicity study in mice, 3 cases of adenocarcinoma in the endometrium were seen in the mid dose group with a statistically significant increase, corresponding to an exposure ratio of 97-fold.
I 2. behandlingsserie var incidensen af infusionsrelaterede reaktioner lavere hos patienter, der fik Gazyvaro plus bendamustin (24%) sammenlignet med patienter, der fik bendamustin alene (32%).
During Cycle 2, the incidence of IRRs was lower in patients receiving G+B (24%) compared to patients receiving bendamustine (B) alone (32%).
I 20 hovedundersøgelser hos over 9 000 patienter så man nærmere på Humiras evne til mindske symptomerne på betændelsestilstande.
More than twenty main studies involving over 9,000 patients have looked at the effects of Humira in reducing symptoms of inflammatory conditions.
I 20 ud af disse tilfælde blev der rapporteret paræstesi inden for en til tre dage efter vaccination, herunder 17 tilfælde, hvor paræstesi var det primære symptom.
Of those cases 20 reported paraesthesia within one to three days of vaccination, including 17 cases where paraesthesia was the primary symptom.
I 20-ugers studiet (n = 225) blev der ikke observeret nogen signifikant forskel i det primære virkningsendepunkt, dvs. proportionen af patienter, der havde brug for blodtransfusion med røde blodlegemer efter dag 28 (62 % af epoetin alfa-patienter sammenlignet med 69 % af patienterne i standardbehandling).
In the 20-week study (n = 225), no significant difference was observed in the primary efficacy endpoint, i.e. the proportion of patients who required a RBC transfusion after Day 28 (62% of epoetin alfa patients versus 69% of standard therapy patients).
I 2016 vurderede CVMP, at de indsendte data gjorde det muligt at ændre BTVPUR AlSap 1-8 til en BTVPUR-vaccine baseret på tre mulige serotyper med en eller to udvalgte serotyper, afhængigt af behovet.
In 2016 the CVMP considered that data submitted allowed BTVPUR AlSap 1-8 to convert to a BTVPUR vaccine based on three possible serotypes with one or two serotypes selected depending on the need.
I 24 timer efter indgivelse af denne medicin skal du beskytte dine øjne og huden mod for kraftigt lys (for eksempel direkte sollys eller indendørsbelysning med kraftig fokus).
For 24 hours after administration of this medicine, protect your eyes and skin from strong light (for example direct sunlight or brightly focused indoor light).
I 27 rapporter om administration af Fluenz hos gravide kvinder i et amerikansk system til rapportering af bivirkninger ved vacciner observeredes ingen usædvanlige mønstre med graviditetskomplikationer eller resultater hos fostret.
In 27 reports of Fluenz administration to pregnant women from the US Vaccine Adverse Event Reporting System, no unusual patterns of pregnancy complications or foetal outcomes were observed.
I 27 rapporter om administration af T/LAIV til gravide kvinder i et amerikansk system til rapportering af bivirkninger ved vacciner (VAERS) observeredes ingen usædvanlige mønstre for graviditetskomplikationer eller eksponerede fostre.
In 27 reports of T/LAIV administration to pregnant women from the US Vaccine Adverse Event Reporting System (VAERS), no unusual patterns of pregnancy complications or foetal outcomes were observed.
I 3 pivotale kliniske studier, hvor adjuverende Herceptin blev administreret i kombination med kemoterapi, var hyppigheden af kardiel dysfunktion af grad 3/4 (især symptomatisk kongestiv hjerteinsufficiens) tilsvarende hos patienter, der fik administreret kemoterapi alene (dvs. som ikke fik Herceptin), som hos patienter, der fik Herceptin sekventielt til taxan (0,3-0,4 %).
In 3 pivotal clinical trials of adjuvant Herceptin given in combination with chemotherapy, the incidence of grade 3/4 cardiac dysfunction (specifically symptomatic Congestive Heart Failure) was similar in patients who were administered chemotherapy alone (ie did not receive Herceptin) and in patients who were administered Herceptin sequentially after a taxane (0.3-0.4 %).
I 3 specifikke lægemiddel- lægemiddel interaktionsundersøgelser blev alfa-blokkeren doxazosin (4 mg og 8 mg) og sildenafil (25 mg, 50 mg eller 100 mg) administreret samtidig hos patienter med benign prostatahyperplasi (BPH) stabiliseret på dosazosinbehandling.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
I 3 specifikke lægemiddel- lægemiddel interaktionsundersøgelser blev alfa-blokkeren doxazosin (4 mg og 8 mg) og sildenafil (25 mg, 50 mg eller 100 mg) anvendt samtidigt hos patienter med benign prostatahyperplasi (BPH) stabiliseret på doxazosinbehandling.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
i 3-4 dage eller mere, indtil smerte og
age of 6) for 3 – 4 days or more until
i 3-4 dage eller mere, indtil smerte og
of 6) for 3 – 4 days or more until pain
i 3-4 dage eller mere, indtil smerte og
of 6) for 3 – 4 days or more until pain and
I 34 % af behandlingsperioderne med alvorlig neutropeni var varigheden > 7 dage.
In 34 % of courses with severe neutropenia, the duration was > 7 days.
I 4 kliniske undersøgelser der blev gennemført mellem 1992 og 2000 blev PROCOMVAX givet til 1809 spædbørn, der var cirka 2 måneder gamle, og som ikke tidligere havde fået nogen hepatitis B- vaccine.
In 4 clinical trials conducted between 1992 and 2000, PROCOMVAX was administered to 1809 infants, approximately 2 months of age, who had not previously received any hepatitis B vaccine.
I 4 kliniske undersøgelser der blev gennemført mellem 1992 og 2000 blev PROCOMVAX givet til 722 spædbørn, der var cirka 2 måneder gamle, og som tidligere havde fået en enkelt dosis hepatitis B- vaccine ved fødslen.
In 4 clinical trials conducted between 1992 and 2000, PROCOMVAX was administered to 722 infants, approximately 2 months of age, who had previously received a single dose of hepatitis B vaccine at birth.
I 4 kontrollerede og 2 ikke-kontrollerede kliniske studier blev 530 voksne kroniske ITP-patienter behandlet med eltrombopag.
In 4 controlled and 2 uncontrolled clinical studies, 530 chronic adult ITP patients were treated with eltrombopag.
I 4 timer før du tager Revolade…
For 4 hours before you take Revolade...
i 4 uger
for 4 weeks
i 4 uger før behandlingen påbegyndes
for 4 weeks before starting treatment
I 40 % af tilfældene fortsatte symptomerne dog i den fulde 6 måneders periode.
However in 40% of cases symptoms continued for the entire 6- month period.
I 46 % af behandlingsperioderne med moderat til alvorlig anæmi var varigheden > 7 dage.
In 46 % of courses with moderate to severe anaemia, the duration was > 7 days.
i 48 uger dobbeltblind adefovirdipivoxil, efterfulgt af 144 uger open-label tenofovirdisoproxilfumarat.
i 48 weeks of double-blind adefovir dipivoxil followed by 144 weeks open-label tenofovir disoproxil fumarate.
i 48 uger dobbeltblind tenofovirdisoproxilfumarat, efterfulgt af 192 uger open-label.
i 48 weeks of double-blind tenofovir disoproxil fumarate followed by 192 weeks open-label.
i 5 dage
for 5 days
I 5 fase II kliniske studier med patienter med resistens eller intolerans over for tidligere behandling med imatinib blev der taget gentagen ekg ved baseline samt under studiet på præspecificerede tidspunkter på 865 patienter, der fik SPRYCEL 70 mg 2 mg to gange dagligt.
In 5 Phase II clinical studies in patients with resistance or intolerance to prior imatinib therapy, repeated baseline and on-treatment ECGs were obtained at pre-specified time points and read centrally for 865 patients receiving SPRYCEL 70 mg twice daily.
I 5 tilfælde var bleghed forbundet med systemiske hændelser såsom hypotension, som i forvejen er identificeret som en bivirkning ved Mirvaso.
In 5 cases pallor was associated with systemic events such as hypotension which is already an identified adverse drug reaction of Mirvaso.
I 6 måneders studiet, oplevede patienter, som fik Bretaris Genuair 322 µg to gange dagligt, en klinisk relevant forbedring i deres lungefunktion, målt ved FEV1.
In the 6-month study, patients receiving Bretaris Genuair 322 µg twice daily experienced a clinically meaningful improvement in their lung function (as measured by FEV1).
I 6 måneders studiet, oplevede patienter, som fik Eklira Genuair 322 µg to gange dagligt, en klinisk relevant forbedring i deres lungefunktion, målt ved FEV1.
In the 6-month study, patients receiving Eklira Genuair 322 µg twice daily experienced a clinically meaningful improvement in their lung function (as measured by FEV1).
I 6 uger efter du er stoppet med at tage CellCept.
For 6 weeks after you stop taking CellCept.
I 6 uger efter du er stoppet med at tage Myclausen.
For 6 weeks after you stop taking Myclausen.
I 6 uger efter du er stoppet med at tage Mycophenolate mofetil Teva.
For 6°weeks after you stop taking Mycophenolate mofetil Teva.
I 6 uger efter du er stoppet med at tage Myfenax.
For 6°weeks after you stop taking Myfenax.
I 6-måneders karcinogenicitetsforsøg med transgene mus var der øget incidens af benigne granulosa- celletumorer i ovarierne hos hunmus, der fik 150 eller 500 mg/kg/dag.
In 6-month carcinogenicity studies in transgenic mice, there was an increased incidence of benign, ovarian granulosa-cell tumours in female mice given 150 or 500 mg/kg/day.
I 64-ugers-studiet blev der inkluderet patienter med svær til meget svær KOL.
In the 64-week study patients were enrolled who had severe to very severe COPD.
I 7 dage efter sidste dosis.
For 7 days following final dose
I 8 tilfælde forsvandt bivirkninger i urinvejene efter seponering af UMEC/VI.
In 8 cases, there was evidence of positive dechallenge following discontinuation of UMEC/VI.
I Abraxan er paclitaxel i modsætning til konventionelle lægemidler, der indeholder paclitaxel, bundet til det humane protein albumin i bittesmå partikler, der kaldes for nanopartikler.
In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles’.
I ACTG 245, et dobbeltblindet, placebokontrolleret studie, var forekomsten af alvorlig, lægemiddelrelateret granulocytopeni 5/305 (1,6 %).
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6 %).
I ACTG 245, et dobbeltblindt, placebokontrolleret studie, var forekomsten af alvorlig, lægemiddelrelateret granulocytopeni 5/305 (1,6%).
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6%).
I ACTIVE-A, var antallet af større blødninger større i clopidogrel + ASA-gruppen end i placebo + ASA- gruppen (6,7 % versus 4,3 %).
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
I ACTIVE-A, var antallet af større blødninger større i clopidogrel + ASA-gruppen end i placebo + ASA-gruppen (6,7 % versus 4,3 %).
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
I ADVANCE MPI 1 og ADVANCE MPI 2 var der signifikante forskelle ved sammenligning af følgende forhåndsdefinerede endepunkter for sikkerhed og tolerabilitet af Rapiscan og adenosin: (1) en summeret scoring af tilstedeværelse og sværhedsgrad af symptomgrupperne rødmen, brystsmerter og dyspnø var lavere med Rapiscan (0,9 ± 0,03) end med adenosin (1,3 ± 0,05); og (2) symptomgrupperne rødmen (21% versus 32%), brystsmerter (28% versus 40%), og ‘svælg-, hals- eller kæbesmerter’ (7% versus 13%) var mindre hyppige med Rapiscan; forekomsten af hovedpine (25% versus 16%) var hyppigere med Rapiscan.
In ADVANCE MPI 1 and ADVANCE MPI 2, the following pre-specified safety and tolerability endpoints comparing Rapiscan to adenosine achieved statistical significance: (1) a summed score of both the presence and severity of the symptom groups of flushing, chest pain, and dyspnoea was lower with Rapiscan (0.9 ± 0.03) than with adenosine (1.3 ± 0.05); and (2) the symptom groups of flushing (21% vs 32%), chest pain (28% vs 40%), and ‘throat, neck or jaw pain’ (7% vs 13%) were less frequent with Rapiscan; the incidence of headache (25% vs 16%) was more frequent with Rapiscan.